Pulmonary Medicine - Global Oncology Academy

1-16 of 67

Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Project Oncology®
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Project Oncology®
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
Managing Brain Metastases in ALK+ NSCLC
Managing Brain Metastases in ALK+ NSCLC
Project Oncology®
Managing Brain Metastases in ALK+ NSCLC
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Project Oncology®
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Charles Turck, PharmD, BCPS, BCCCP; Martin Dietrich, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Martin Dietrich, MD, PhD
Early Detection Shapes Outcomes in Post-Transplant Lung Cancer
Early Detection Shapes Outcomes in Post-Transplant Lung Cancer
Project Oncology®
Early Detection Shapes Outcomes in Post-Transplant Lung Cancer
The Epigenetics of Lung Cancer Dormancy and Relapse
The Epigenetics of Lung Cancer Dormancy and Relapse
Project Oncology®
The Epigenetics of Lung Cancer Dormancy and Relapse
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstracts
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Ryan Quigley
- Ryan Quigley
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Oncogenic Drivers in Never-Smokers with NSCLC
Oncogenic Drivers in Never-Smokers with NSCLC
Project Oncology®
Oncogenic Drivers in Never-Smokers with NSCLC
Apar Kishor Ganti, MD, MS
- Apar Kishor Ganti, MD, MS
Expanding Molecular Testing in Community NSCLC Care
Expanding Molecular Testing in Community NSCLC Care
Project Oncology®
Expanding Molecular Testing in Community NSCLC Care
Apar Kishor Ganti, MD, MS
- Apar Kishor Ganti, MD, MS
Recognizing High-Risk Profiles for NSCLC
Recognizing High-Risk Profiles for NSCLC
Project Oncology®
Recognizing High-Risk Profiles for NSCLC
Jobelle Baldonado, MD
- Jobelle Baldonado, MD
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Project Oncology®
Modern Management of ROS1-Positive Non-Small Cell Lung Cancer
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
AudioAbstracts
Understanding Safety Profiles of ROS1 TKIs in Advanced Non-Small Cell Lung Cancer
Ryan Quigley
- Ryan Quigley
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Project Oncology®
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Jacob Sands, MD; Julia Rotow, MD
- Jacob Sands, MD
- Julia Rotow, MD
- Xiuning Le, MD, PhD
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Project Oncology®
Dato-DXd’s Intracranial Efficacy in NSCLC: Insights from TROPION-Lung01
Jacob Sands, MD; Aaron Lisberg, MD
- Jacob Sands, MD
- Aaron Lisberg, MD

Prev
1
2
3
4
5
Next

1/5